Kymera Therapeutics (KYMR) Change in Acquisitions & Divestments (2020 - 2026)

Kymera Therapeutics (KYMR) has reported Change in Acquisitions & Divestments for 7 consecutive years, with $133.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 0.85% year-over-year to $133.9 million; the TTM figure through Mar 2026 stood at $489.1 million (down 9.96% YoY), while the FY2025 annual figure was $488.0 million, down 4.31% from the prior year.
• Change in Acquisitions & Divestments improved to $133.9 million in Q1 2026 per KYMR's latest filing, from $103.9 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $147.9 million in Q4 2024 and bottomed at $76.1 million in Q4 2023.
• Historically, Change in Acquisitions & Divestments has averaged $115.6 million across 5 years, with a median of $117.7 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments slumped 32.6% — and 2024, when it jumped 94.43%.
• Kymera Therapeutics' Change in Acquisitions & Divestments stood at $97.9 million in 2022, then slipped by 22.32% to $76.1 million in 2023, then surged by 94.43% to $147.9 million in 2024, then slipped by 29.78% to $103.9 million in 2025, then grew by 28.87% to $133.9 million in 2026.
• Business Quant data shows KYMR's Change in Acquisitions & Divestments at $133.9 million in Q1 2026, $103.9 million in Q4 2025, and $132.4 million in Q3 2025.